Onkos Surgical, Inc. announced today that it signed a 4-year agreement with 3D Systems (NYSE: DDD) to advance the delivery of personalized surgical solutions and help improve patient outcomes.
Press Release
1315 Capital, LLC, an expansion and growth equity firm that invests in commercial-stage specialty pharmaceutical, medical technology and healthcare services companies, today announced the single close of 1315 Capital II, a healthcare growth equity fund, at its hard cap over $300 million, exceeding its $250 million target. Similar to the first fund, 1315 Capital II …
Colorescience®, the leading dermatologist-recommended skin health-focused skincare and cosmetics company, is proud to introduce the innovative Colorescience Total Eye™ 3-in-1 Renewal Therapy SPF 35. This comprehensive eye product is a strong addition to the brand’s treatment portfolio that includes All Calm™ Clinical Redness Corrector SPF 50, which addresses symptoms of adult acne and rosacea, and …
Genoptix, Inc., a leading oncology diagnostic laboratory, and Rosetta Genomics Ltd. (ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, jointly announce that they have entered into a definitive merger agreement under which Genoptix will acquire all of the outstanding shares of Rosetta Genomics for a …
“Encore is excited about adding another great product to our portfolio and looking forward to the opportunity to commercialize a new product for the treatment of mild to moderate psoriasis as well as broadening our portfolio outside of atopic dermatitis and acne,” said Robert Moccia, CEO, Encore Dermatology, Inc.
Onkos Surgical, Inc., a specialty medtech company dedicated to advancing innovation for the surgical oncology market announced today that it will launch a new service platform focused on preoperative surgical planning called Precision Oncology. The company will showcase the new platform at the upcoming Musculoskeletal Tumor Society (MSTS) held in Denver, Colorado.
Colorescience®, the leading dermatologist-recommended skin health cosmetics company, has earned a Fall Beauty O-Ward for their new All Calm™ Clinical Redness Corrector SPF 50, launched in August 2017. A first-and-only product created to instantly neutralize redness and soothe sensitive skin, it was created to offer immediate color correction, chemical-free SPF 50 UVA/UVB sun protection, and …
Nutrition 21, LLC is pleased to announce its expanded partnership with American Media, Inc. (AMI) that is dedicated to educating consumers on the benefits of Nitrosigine. Nitrosigine is scientifically engineered to significantly boost nitric oxide levels, a key factor in increasing blood flow to working muscles^ and is formulated to help consumers train longer, harder …
Colorescience®, the leading dermatologist-recommended skin health cosmetics company, is proud to introduce the innovative All Calm™ Clinical Redness Corrector. Formulated for redness, rosacea and sensitive skin, this first-of-its-kind formula instantly calms and soothes skin while its subtle green undertones neutralize redness, and its patent-pending BioSolaceTM complex helps provide ongoing relief from sensitivity and the appearance …
Colorescience®, the leading dermatologist-recommended skin health cosmetics company, today announced the successful completion of a $15 Million Series C Preferred Stock financing led by 1315 Capital, L.P., a Philadelphia-based healthcare investment firm that specializes in providing expansion and growth capital to specialty pharmaceutical, medical technology, and healthcare services companies.
Nutrition 21’s patented ingredient combining amylopectin and chromium, brand named Velositol, has attained GRAS (generally recognized as safe) status after an extensive and rigorous review of the scientific dossier and safety data conducted by Intertek Health Sciences, Inc.
Genoptix, Inc., a leading oncology diagnostics laboratory and informatics company, today announced that it offers three diagnostic tests that support immunotherapy decisions for solid tumor cancers.